Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma

Mark Ball, MD

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.